Together, these future studies would help clarify the cancer- versus the immune-mediated effects of NRF2 activation and may identify new therapeutic targets or biomarkers for stratifying patients likely to benefit from triterpenoid-based therapies. This evidence concerns the gene NFE2L2 and cancer.